TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial
Brief Summary: The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.


Options:
A: Arm Label: Bemiparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bemiparin, Drug: Enoxaparin | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): Bemiparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Bemiparin, Enoxaparin
B: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
C: Arm Label: low molecular weight heparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin Sodium | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin Sodium; Assigned to Arm(s): low molecular weight heparin
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: dalteparin sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin sodium | Intervention Type: DRUG; Name: dalteparin sodium; Assigned to Arm(s): dalteparin sodium

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of an Afro-centric Dance Program for African-American Daughters and Mothers
Brief Summary: The purpose of this study is to examine the feasibility and efficacy of a 12-week afterschool afro-centric dance physical activity program for daughters and mothers on the physical activity level of African-American girls.


Options:
A: Arm Label: Center-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Center-based Intervention | Arm Label: Center-and-home-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based Intervention | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: Center-based Intervention; Assigned to Arm(s): Center-based intervention | Intervention Type: BEHAVIORAL; Name: Home-based Intervention; Assigned to Arm(s): Center-and-home-based intervention | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active Control
B: Arm Label: CHAMP group; Type: EXPERIMENTAL; Interventions: Behavioral: CHAMP | Arm Label: CHAMP+ group; Type: EXPERIMENTAL; Interventions: Behavioral: CHAMP, Behavioral: CHAMP+ | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHAMP; Assigned to Arm(s): CHAMP group, CHAMP+ group | Intervention Type: BEHAVIORAL; Name: CHAMP+; Assigned to Arm(s): CHAMP+ group
C: Arm Label: School Only; Type: EXPERIMENTAL; Interventions: Behavioral: School | Arm Label: School + Family; Type: EXPERIMENTAL; Interventions: Behavioral: School, Behavioral: Family | Arm Label: School + About Eating; Type: EXPERIMENTAL; Interventions: Behavioral: School, Behavioral: About Eating | Arm Label: School + Family + About Eating; Type: EXPERIMENTAL; Interventions: Behavioral: School, Behavioral: Family, Behavioral: About Eating | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: School; Assigned to Arm(s): School + About Eating, School + Family, School + Family + About Eating, School Only | Intervention Type: BEHAVIORAL; Name: Family; Assigned to Arm(s): School + Family, School + Family + About Eating | Intervention Type: BEHAVIORAL; Name: About Eating; Assigned to Arm(s): School + About Eating, School + Family + About Eating
D: Arm Label: Girls and mothers dance together; Type: EXPERIMENTAL; Interventions: Behavioral: Girls and mothers Afro-centric dance program | Arm Label: Girls, alone; Type: EXPERIMENTAL; Interventions: Behavioral: Girls, alone | Arm Label: No dancing; Type: ACTIVE_COMPARATOR; Interventions: Other: Newsletter | Intervention Type: BEHAVIORAL; Name: Girls and mothers Afro-centric dance program; Assigned to Arm(s): Girls and mothers dance together | Intervention Type: BEHAVIORAL; Name: Girls, alone; Assigned to Arm(s): Girls, alone | Intervention Type: OTHER; Name: Newsletter; Assigned to Arm(s): No dancing

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function
Brief Summary: This research study will examine brain glucose metabolism after an overnight fast to determine the effect of exenatide on brain glucose metabolism and lipid metabolism.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo
D: Arm Label: Exenatide first, then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Exenatide, Drug: Placebo | Arm Label: Placebo first, then Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide, Drug: Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide first, then Placebo, Placebo first, then Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Exenatide first, then Placebo, Placebo first, then Exenatide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Histological Comparison of Healing Following Tooth Extraction With Ridge Preservation Using Cortical Versus Cancellous Freeze Dried Bone Allograft
Brief Summary: The purpose of this study is to compare cortical and cancellous freeze-dried bone allograft (FDBA) materials in the preservation of alveolar bone following extraction of non-molar teeth. The primary objective is to histologically evaluate and compare the healing of extraction sockets of non-molar teeth grafted with cortical FDBA versus cancellous FDBA for ridge preservation.


Options:
A: Arm Label: natural healing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Alveolar Ridge Preservation; Type: EXPERIMENTAL; Interventions: Device: Alveolar Ridge Preservation | Arm Label: Immediate Implant + Alveolar Ridge Preservation; Type: EXPERIMENTAL; Interventions: Device: Alveolar Ridge Preservation | Intervention Type: DEVICE; Name: Alveolar Ridge Preservation; Assigned to Arm(s): Alveolar Ridge Preservation, Immediate Implant + Alveolar Ridge Preservation
B: Arm Label: L-PRF group; Type: EXPERIMENTAL; Interventions: Procedure: Platelet-rich fibrin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Platelet-rich fibrin; Assigned to Arm(s): L-PRF group
C: Arm Label: Combination 50% cortical/50% cancellous FDBA; Type: EXPERIMENTAL; Interventions: Device: 50% cortical/50% cancellous FDBA | Arm Label: 100% cortical FDBA; Type: ACTIVE_COMPARATOR; Interventions: Device: 100% cortical FDBA | Arm Label: 100% cancellous FDBA; Type: ACTIVE_COMPARATOR; Interventions: Device: 100% cancellous FDBA | Intervention Type: DEVICE; Name: 50% cortical/50% cancellous FDBA; Assigned to Arm(s): Combination 50% cortical/50% cancellous FDBA | Intervention Type: DEVICE; Name: 100% cortical FDBA; Assigned to Arm(s): 100% cortical FDBA | Intervention Type: DEVICE; Name: 100% cancellous FDBA; Assigned to Arm(s): 100% cancellous FDBA
D: Arm Label: cancellous FDBA (LifeNet); Type: EXPERIMENTAL; Interventions: Device: Cancellous FDBA | Arm Label: cortical FDBA (LifeNet); Type: EXPERIMENTAL; Interventions: Device: cortical FDBA | Intervention Type: DEVICE; Name: cortical FDBA; Assigned to Arm(s): cortical FDBA (LifeNet) | Intervention Type: DEVICE; Name: Cancellous FDBA; Assigned to Arm(s): cancellous FDBA (LifeNet)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder
Brief Summary: The purpose of this study is to compare which of the two mood stabilizers (drugs that help to steady/stabilize mood in patients with bipolar disorder (BD)), lithium and divalproex, is more effective in patients with bipolar disorder over 26 weeks. The study will also compare if lithium or divalproex used alone versus lithium or divalproex used with quetiapine versus lithium or divalproex used with lamotrigine is more effective when symptoms of depression develop.


Options:
A: Intervention Type: BEHAVIORAL; Name: Psychoeduction; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: lamotrigine | Arm Label: lamotrigine; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1; Type: OTHER; Interventions: Drug: lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): Arm 1
D: Arm Label: Lithium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium | Arm Label: Divalproex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex | Arm Label: Lithium plus Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium, Drug: Quetiapine | Arm Label: Lithium plus Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium, Drug: Lamotrigine | Arm Label: Divalproex plus Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex, Drug: Quetiapine | Arm Label: Divalproex plus Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex, Drug: Lamotrigine | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium, Lithium plus Lamotrigine, Lithium plus Quetiapine | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): Divalproex, Divalproex plus Lamotrigine, Divalproex plus Quetiapine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Divalproex plus Lamotrigine, Lithium plus Lamotrigine | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Divalproex plus Quetiapine, Lithium plus Quetiapine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Videos to Facilitate Advance Care Planning for Patients With Heart Failure
Brief Summary: The purpose of this study is to compare the decision making of subjects with advanced CHF having a verbal discussion about goals of care compared to subjects using a video.


Options:
A: Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention (ACP) arm; Type: EXPERIMENTAL; Interventions: Behavioral: ACP | Intervention Type: BEHAVIORAL; Name: ACP; Assigned to Arm(s): Intervention (ACP) arm
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Video Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Video decision aid | Intervention Type: BEHAVIORAL; Name: Video decision aid; Assigned to Arm(s): Video Arm
C: Arm Label: Integrated care; Type: EXPERIMENTAL; Interventions: Other: Integrated care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated care; Assigned to Arm(s): Integrated care | Intervention Type: OTHER; Name: Integrated care; Assigned to Arm(s): Integrated care
D: Arm Label: Intervention: ACP conversation; Type: EXPERIMENTAL; Interventions: Behavioral: ACp conversation | Arm Label: No intervention: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACp conversation; Assigned to Arm(s): Intervention: ACP conversation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Options:
A: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
B: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
C: Arm Label: Innohep®; Type: EXPERIMENTAL; Interventions: Drug: Innohep® | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Innohep®; Assigned to Arm(s): Innohep®
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Options:
A: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin
C: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
D: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Options:
A: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
C: Arm Label: Innohep®; Type: EXPERIMENTAL; Interventions: Drug: Innohep® | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Innohep®; Assigned to Arm(s): Innohep®
D: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): A, B, C
B: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
C: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
D: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Options:
A: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A

Answer: C